Liver study tests how body handles experimental drug
NCT ID NCT06442436
First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 5 times
Summary
This early-stage study looks at how the experimental drug nemtabrutinib is processed in people with moderate liver impairment compared to healthy volunteers. About 32 adults will receive a single oral dose, and researchers will measure drug levels in the blood over time. The goal is to gather safety and dosing information, not to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nemtabrutinib (a drug taken by mouth)
- What this could lead to
- If successful, this study could help doctors understand how to dose nemtabrutinib safely for patients with liver problems.
- What could go wrong
- This is a very early, small Phase 1 study with only 32 participants. It is not designed to test whether the drug works for any disease, only how the body handles it.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT (HI) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clinical Pharmacology of Miami ( Site 0003)
Miami, Florida, 33172, United States
-
Orlando Clinical Research Center ( Site 0001)
Orlando, Florida, 32809, United States
-
Texas Liver Institute ( Site 0002)
San Antonio, Texas, 78215, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.